No black box warning on record for Silodosin

As of the latest FDA labeling reviewed, Silodosin (SILODOSIN) does not carry a black box warning. Standard warnings and precautions still apply — see the full Silodosin medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Postural hypotension, with or without symptoms (e.g., dizziness), may develop when beginning silodosin treatment. ( 5.1 ) In patients with moderate renal impairment, silodosin dose should be reduced to 4 mg once daily. ( 5.2 ) Silodosin should not be used in combination with other alpha-blockers. ( 5.5 ) Examine patients thought to have BPH prior to starting therapy with

No black box warning on record for Silodosin

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Postural hypotension, with or without symptoms (e.g., dizziness), may develop when beginning silodosin treatment. ( 5.1 ) In patients with moderate renal impairment, silodosin dose should be reduced to 4 mg once daily. ( 5.2 ) Silodosin should not be used in combination with other alpha-blockers. ( 5.5 ) Examine patients thought to have BPH prior to starting therapy with

Silodosin Black Box Warning

No black box warning on record for Silodosin

Other warnings & precautions

Silodosin Black Box Warning

No black box warning on record for Silodosin

Other warnings & precautions